Latest Trials Latest NewsFAQ

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Longitudinal Study of Multiple Symptoms in Advanced Lung Cancer

Completed

Conditions: Lung Cancer

Interventions: Behavioral: Questionnaire
Behavioral: Telephone Interactive System
Other: Blood Samples

First Posted Date: 2007-01-17

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 204

Registration Number: NCT00422500

Locations: 🇺🇸
Jackson Memorial Hospital, Miami, Florida, United States
🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

Phase 2

Completed

Conditions: Leukemia
Acute Myeloid Leukemia
AML

Interventions: Drug: Cytarabine
Drug: Idarubicin

First Posted Date: 2007-01-17

Last Posted Date: 2018-08-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 175

Registration Number: NCT00422591

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

2 Arm Study of Clofarabine IV in MDS Patients

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Leukemia

Interventions: Drug: Clofarabine

First Posted Date: 2007-01-15

Last Posted Date: 2012-07-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00422032

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Combined Strength Training and Functional Endurance Exercise Regimen on Cancer -Related Fatigue and Physical Performance

Completed

Conditions: Breast Cancer
Fatigue

Interventions: Behavioral: Combined Strength Training and Functional Endurance Exercise
Behavioral: Questionnaire

First Posted Date: 2007-01-11

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00421057

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Bone Response in Metastatic Breast Cancer Involving Bones

Completed

Conditions: Breast Cancer
Bone Metastases

Interventions: Procedure: Skeletal Scintigraphy
Procedure: Radiography
Procedure: CT Scan

First Posted Date: 2007-01-11

Last Posted Date: 2016-02-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00420433

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Liposomal amphotericin B
Drug: Voriconazole

First Posted Date: 2007-01-05

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT00418951

Locations: 🇺🇸
The University of Texas M D Anderson Cancer Center, Houston, Texas, United States

Gliogene: Brain Tumor Linkage Study

Conditions: Brain Tumor
Glioma

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-01-05

Last Posted Date: 2020-12-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17080

Registration Number: NCT00418899

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇮🇱
The Danek Gertner Institute, Tel Hashomer, Israel
🇸🇪
Umeå University Hospital, Umeå, Sweden

and more 12 locations

Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning

Phase 3

Terminated

Conditions: Brain Tumor

Interventions: Drug: SR Methylphenidate
Drug: IR Methylphenidate
Drug: Modafinil

First Posted Date: 2007-01-05

Last Posted Date: 2020-09-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT00418691

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Respiratory Tumor and Normal Tissue Motion

Completed

Conditions: Lung Cancer
Abdominal Cancer

Interventions: Procedure: Motion CT Scans

First Posted Date: 2006-12-25

Last Posted Date: 2012-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 86

Registration Number: NCT00415675

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

Phase 2

Terminated

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Imatinib Mesylate (IM)
Drug: TALL-104 cells

First Posted Date: 2006-12-25

Last Posted Date: 2014-06-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00415909

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy